¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fragment length mapping"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mapping
    ÁöµµÈ­, ÁöµµÀÛ¼º
  • spot mapping
    ȯÀڹ߻ýÁöµµÀÛ¼º
  • crown-heel length
    ¸Ó¸®¹ß²ÞÄ¡±æÀÌ, Á¤Á¾Àå
  • crown-rump length
    ¸Ó¸®¾ûµ¢±æÀÌ, Á¤µÐÀå
  • focal length
    ÃÊÁ¡°Å¸®, ÃÊÁ¡±æÀÌ
  • force velocity length relation
    Èû¼Óµµ±æÀ̰ü°è
  • length
    ±æÀÌ
  • length bias
    ±â°£Â÷À̹ÙÀ̾
  • length-height index
    ¸Ó¸®³ôÀ̱æÀÌÁö¼ö
  • quarter wave length matching
    »çºÐÇÒÆÄÁ¶È­
  • stride length
    °ÉÀ½°Å¸®
  • short-wave length perimetry
    ´ÜÆÄÀå½Ã¾ßÃøÁ¤(¹ý)
  • wave length
    ÆÄÀå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • length bias
    ±â°£Â÷À̹ÙÀ̾
  • crown-heel length
    ¸Ó¸®¹ß²ÞÄ¡±æÀÌ
  • crown-rump length
    ¸Ó¸®¾ûµ¢±æÀÌ
  • tension length curve
    Àå·Â±æÀ̰
  • tension length diagram curve
    Àå·Â±æÀ̵µÇ¥°î¼±
  • length tension diagram
    ±æÀÌÀå·Â±×¸²Ç¥
  • tension length diagram
    Àå·Â±æÀ̵µÇ¥
  • focal length
    ÃÊÁ¡°Å¸®, ÃÊÁ¡±æÀÌ
  • force velocity length relation
    Èû¼Óµµ±æÀ̰ü°è
  • length-height index
    (¢¡altitudinal index) ¸Ó¸®³ôÀ̱æÀÌÁö¼ö
  • length
    ±æÀÌ
  • stride length
    °ÉÀ½°Å¸®
  • wave length
    (¢¡wavelength) ÆÄÀå
  • quarter wave length matching
    »çºÐÇÒÆÄÁ¶È­
  • short-wave length perimetry
    ´ÜÆÄÀå½Ã¾ßÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • height length index
    ¼öÁ÷Áö¼ö(á÷òÁò¦â¦).
  • initial length
    ¿ø·¡±æÀÌ ¡ì±Ù(ÐÉ)ÀÇ¡í.
  • quarter wave length matching
    4 ºÐÇÒÆÄ Á¶È­
  • quarter-wave length matching
    4-ºÐÇÒÆÄ Á¶È­ (ÞÌ-ÝÂùÜ÷î ðàûú)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • color mapping
    »öÁ¶ ÁöµµÈ­
  • detached fragment
    À¯¸®(°ñ)Æí(ë´ìÆÍéø¸).
  • fallen fragment sign
    ³«ÇÏ ÆÄÆí ¡ÈÄ
  • fracture fragment
    °ñÀý Æí(Íéï¹ø¸).
  • fragment
    ÀýÆí, ºÐÀý, Á¶°¢
  • fragment
    ¼¼Æí, ÆÄÆí(÷òø¸), ´ÜÆí(Ó¨ø¸), ºÐÀý, ÆíÀý, °ñÆí(Íéø¸).
  • mapping
    ÁöµµÈ­
  • mapping test
    Áö¸®(ÇÐ)Àû ½ÃÇè(ò¢ìµùÊîÜ ãËúÐ).
  • mapping test
    Áö¸®(ÇÐ)Àû ½ÃÇè(ò¢ìµ(ùÊ)îÜ ãËúÐ).
  • spot mapping
    Á¡µµ¹ý.
  • urinary gonadotropin fragment/peptide
    ¿äÁß¼º¼±ÀÚ±ØÈ£¸£¸óºÐÀý/ÆéƼµå
  • arm length
    »óÁö Àå(ß¾ò¶íþ), »óÁö ±æÀÌ, ÆÈ ±æÀÌ.
  • average length of life
    Æò±Õ¼ö¸í(̰˻ËÛËÎ).
  • average length of stay
    Æò±Õ Àç¿øÀϼö
  • axial length
    ¾È±¸±æÀÌ, ¾ÈÃàÀå
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crystallizable fragment
    "°áÁ¤(Ì¿ïÜ) Á¶°¢, (ÔÒ) fc fragment"
  • Fab fragment
    Fab Á¶°¢
  • Fab' fragment
    Fab' Á¶°¢
  • F(ab')2 fragment
    F(ab')2 Á¶°¢
  • Fc fragment
    Fc Á¶°¢
  • Fd fragment
    Fd Á¶°¢
  • Fd' fragment
    Fd' Á¶°¢
  • (F1+F2) fragment
    (F1 + F2) Á¶°¢
  • F1 fragment
    F1 Á¶°¢
  • F2 fragment
    F2 Á¶°¢
  • F3 fragment
    F3 Á¶°¢
  • fragment ion
    Á¶°¢ ÀÌ¿Â
  • fragment map
    Á¶°¢ Áöµµ(ò¢Óñ)
  • fragment reaction
    Á¶°¢ ¹ÝÀÀ(Úãëë)
  • Fv fragment
    Fv Á¶°¢
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RELV restriction fragment length variant
RFLP restriction fragment length polymorphism
CR Length Crown to Rump Length
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
UGF Urinary Gonadotropin Fragment
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RFLP Restriction Fragment Length Polymorphic
RFLP Restriction Fragment Length Polymorphism
RFLP restriction enzyme fragment length polymorphism
RFLP Restriction fragment length polymorphism analysis
T-RFLP Terminal Restriction Fragment Length Polymorphism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prodynorphin-derived fragment
    ÇÁ·Î´ÙÀ̳븣ÇÉ À¯·¡ ºÐÀý
  • root fragment
    Ä¡±Ù ÆÄÆí, Ä¡±Ù ÀýÆí
  • average length of life
    Æò±Õ ¼ö¸í
  • crown rump length
    µÎÁ¤ µÐºÎ ±æÀÌ
  • dental length
    Ä¡¿­ÀÇ ±æÀÌ
  • echo train length
    ¿¡ÄÚ ¿­ ±æÀÌ
  • focal length
    ÃÊÁ¡ °Å¸®
    Áý±¤ ·»Áî·ÎºÎÅÍ ÃÖ´ë ÃÊÁ¡ À§Ä¡±îÁöÀÇ °Å¸®.
  • length monitoring system
    ±æÀÌ °¨Áö°è
  • length of dental arch
    Ä¡¿­±Ã ±æÀÌ
  • length of tooth
    Ä¡¾ÆÀå
    Ä¡¾ÆÀÇ ±æÀÌ.
  • optimal length
    ÃÖÀû ±æÀÌ
  • quarter wave length matching
    4 ºÐÇÒÆÄ Á¶È­
  • span length
    ½ºÆÒ ±æÀÌ, ½ºÆÒÀÇ ±æÀÌ
    2°³ÀÇ ÁöÁö´ë »çÀÌ¿¡ ÀÖ´Â º¸ÀÇ ±æÀÌ.
  • spatial pulse length
    °ø°£ ÆÞ½º ±æÀÌ
  • tension-length curve
    Àå·Â ±æÀÌ °î¼±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chromosome mapping The mapping of the relative locations of genes on a chromosome by analysing linkage frequencies (how often different genes are inherited together) and crossover frequencies (how often different combinations of three or more genes are inherited) or recombination frequencies.
(09 Oct 1997)
S1 nuclease mapping A method for locating the 5' end of a transcript in a mixture of RNA.
(05 Mar 2000)
heteroduplex mapping <molecular biology> Heteroduplex mapping is a lab technique used to locate a particular sequence of nucleotides. It involves making a heteroduplex by pairing the unknown nucleic acid strand with a reference strand which has a known sequence.
(09 Oct 1997)
nucleotide mapping Two-dimensional separation and analysis of nucleotides.
(12 Dec 1998)
Okazaki fragment A relatively short (100-1000 bp) fragment of DNA that is later joined by DNA ligase to allow for 3' &rarr; 5' overall chain growth during replication.
(05 Mar 2000)
one-carbon fragment The formyl group or the methyl group that takes part in transformylation or transmethylation reactions; by means of these reactions, a group containing a single carbon atom is added to a compound being biosynthesised, adding a methyl group (as in thymidine formation), adding a hydroxymethyl group (as in serine biosynthesis), or closing a ring (as in purine formation).
(05 Mar 2000)
epitope mapping Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
(12 Dec 1998)
two-carbon fragment The acetyl group (CH3CO-) that takes part in transacetylation reactions with coenzyme A as carrier; commonly referred to as acetate or acetic acid, from which it is derived.
(05 Mar 2000)
f2 fragment <immunology> A fragment of an antibody protein which includes the antigen-binding portions but not the Fc section. They can be produced by treating whole antibodies with proteases that will specifically cleave off the Fc section.
(09 Oct 1997)
Fab fragment The antigen-binding fragment of an immunoglobulin molecule, consisting of both a light chain and part of a heavy chain.
Synonym: Fab piece.
(05 Mar 2000)
Fc fragment <immunology> The constant region on an immunoglobulin molecule. The area that is exactly the same on all antibodies. The region is found on the heavy chains and is not involved in binding antigens.
(09 Oct 1997)
Klenow fragment <molecular biology> Larger part of the bacterial DNA polymerase I (76 kD) that remains after treatment with subtilisin, retains some but not all exonuclease and polymerase activity.
(18 Nov 1997)
fine structure mapping A technique of DNA mapping which makes use of extremely rare recombination events where the crossing over occurs between two genes or two alleles of a gene that are only a few nucleotides apart.
(09 Oct 1997)
fragment A small part broken from a larger entity.
(05 Mar 2000)
fragment reaction A reaction used to assay the activity of peptidyl transferase.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á